English
Anti-PVRIG Neutralizing Antibody
Anti-PVRIG Neutralizing Antibody
Artikelnummer
BPS101712-1
Verpackungseinheit
50 µg
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Applications: Useful for binding and neutralization of PVRIG in ELISA and in cellular assays.
Assay Conditions: The antibody was validated by measuring its binding to a PVRIG antigen in ELISA. PVRIG protein (BPS Bioscience #101712) was coated onto a 96-well plate overnight at 4°C (50 µl/well at a concentration of 2 µg/ml in PBS). The plate was washed 3 times with Immuno Buffer 1 (BPS Bioscience #79311) and blocked using 100 µl of Blocking Buffer 2 (BPS Bioscience #79728) for 1 hour at Room Temperature (RT). After removing the blocking buffer, 50 µl/well of serially diluted CD112R (PVRIG), Fc-Fusion, Avi-Tag, Biotin-Labeled (Human) Recombinant (BPS Bioscience #79270) in Blocking Buffer 2, was added for 1 hour at RT. After 3 washes, the plate was incubated with Streptavidin-HRP (BPS Bioscience #79742), washed again, and colorimetric HRP substrate was added. The reaction was stopped, and absorbance was read at λ=450 nm. The Blank value was subtracted from all values.
Background: PVRIG, also known as Poliovirus receptor related immunoglobulin domain containing protein or CD112R, is a natural killer (NK) cell immune checkpoint receptor, and it is also found in CD8+ T cells. PVRIG works as an inhibitory receptor and recognizes CD112 (also known as poliovirus receptor-related 2, PVRL2 or nectin-2) as its ligand. This binding results in lower responses of NK and T cells towards cancer cells. In T cells it inhibits the nuclear factor of activated T cells (NFAT). Blocking the interaction between PVRIG and its ligand, for instance with an antibody directed towards PVRIG, represents a novel strategy in checkpoint blockade immunotherapy.
Description: This anti-PVRIG (Poliovirus receptor related immunoglobulin domain containing) antibody is a purified, recombinant human monoclonal antibody which recognizes human PVRIG. This recombinant antibody has been tested for specific binding to purified recombinant human PVRIG in an ELISA binding assay.
Format: Aqueous buffer solution.
Formulation: 8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
Purity: ≥90%
Storage Stability: At least 12 months at -80°C.
Uniprot: Q6DKI7
Warnings: Avoid freeze/thaw cycles
Biosafety Level: Not applicable (BSL-1)
Applications: Useful for binding and neutralization of PVRIG in ELISA and in cellular assays.
Assay Conditions: The antibody was validated by measuring its binding to a PVRIG antigen in ELISA. PVRIG protein (BPS Bioscience #101712) was coated onto a 96-well plate overnight at 4°C (50 µl/well at a concentration of 2 µg/ml in PBS). The plate was washed 3 times with Immuno Buffer 1 (BPS Bioscience #79311) and blocked using 100 µl of Blocking Buffer 2 (BPS Bioscience #79728) for 1 hour at Room Temperature (RT). After removing the blocking buffer, 50 µl/well of serially diluted CD112R (PVRIG), Fc-Fusion, Avi-Tag, Biotin-Labeled (Human) Recombinant (BPS Bioscience #79270) in Blocking Buffer 2, was added for 1 hour at RT. After 3 washes, the plate was incubated with Streptavidin-HRP (BPS Bioscience #79742), washed again, and colorimetric HRP substrate was added. The reaction was stopped, and absorbance was read at λ=450 nm. The Blank value was subtracted from all values.
Background: PVRIG, also known as Poliovirus receptor related immunoglobulin domain containing protein or CD112R, is a natural killer (NK) cell immune checkpoint receptor, and it is also found in CD8+ T cells. PVRIG works as an inhibitory receptor and recognizes CD112 (also known as poliovirus receptor-related 2, PVRL2 or nectin-2) as its ligand. This binding results in lower responses of NK and T cells towards cancer cells. In T cells it inhibits the nuclear factor of activated T cells (NFAT). Blocking the interaction between PVRIG and its ligand, for instance with an antibody directed towards PVRIG, represents a novel strategy in checkpoint blockade immunotherapy.
Description: This anti-PVRIG (Poliovirus receptor related immunoglobulin domain containing) antibody is a purified, recombinant human monoclonal antibody which recognizes human PVRIG. This recombinant antibody has been tested for specific binding to purified recombinant human PVRIG in an ELISA binding assay.
Format: Aqueous buffer solution.
Formulation: 8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
Purity: ≥90%
Storage Stability: At least 12 months at -80°C.
Uniprot: Q6DKI7
Warnings: Avoid freeze/thaw cycles
Biosafety Level: Not applicable (BSL-1)
| Artikelnummer | BPS101712-1 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 101712-1 |
| Verpackungseinheit | 50 µg |
| Mengeneinheit | STK |
| Klonalität | Monoclonal |
| Methode | ELISA |
| Isotyp | IgG1 |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
